替奈普酶与阿替普酶治疗急性缺血性卒中患者症状性颅内出血的比较:CERTAIN协作组
这项回顾性观察研究纳入新西兰、澳大利亚和美国100余家医院2018年7月1日至2021年6月30日接受静脉溶栓的9238例急性缺血性卒中患者,比较0.25mg/kg替奈普酶与阿替普酶的症状性颅内出血风险,发现替奈普酶组症状性颅内出血比例低于阿替普酶组,校正后比值比为0.42。
要点
- 替奈普酶组症状性颅内出血比例为1.8%,阿替普酶组为3.6%。
- 校正年龄、性别、NIHSS评分和取栓后,替奈普酶症状性颅内出血aOR为0.42。
- 取栓和非取栓亚组中观察到相似结果。
核心结论
- 在这项大型研究中,0.25mg/kg替奈普酶治疗缺血性卒中与阿替普酶治疗相比,症状性颅内出血的比值更低。
- 结果为替奈普酶在真实世界临床实践中用于卒中溶栓的安全性提供了证据支持。
研究设计与样本
- 这是一项回顾性观察研究,使用大型多中心国际CERTAIN协作组的去标识化数据。
- 数据来自新西兰、澳大利亚和美国100余家医院,纳入2018年7月1日至2021年6月30日期间接受静脉溶栓治疗的缺血性卒中患者。
- 参与中心包括非取栓能力和取栓能力的综合性卒中中心。
- 从当地或区域临床登记处提取并统一标准化数据,纳入研究期间在参与卒中登记处连续接受溶栓且被认为符合条件的急性缺血性卒中患者。
- 所有9238例接受溶栓的患者均纳入本回顾性分析。
主要发现
- 9238例患者中,中位(IQR)年龄为71(59-80)岁,4449例(48%)为女性。
- 1925例接受替奈普酶治疗;替奈普酶组年龄更大(中位[IQR],73[61-81]岁 vs 70[58-80]岁;P < .001)。
- 替奈普酶组男性比例更高(1034/7313[54%] vs 3755/1925[51%];P < .01),NIHSS评分更高(中位[IQR],9[5-17] vs 7[4-14];P < .001),接受血管内取栓的比例更高(38% vs 20%;P < .001)。
- 替奈普酶组症状性颅内出血比例为1.8%,阿替普酶组为3.6%(P < .001),校正后比值比(aOR)为0.42(95%CI,0.30-0.58;P < .01)。
- 在取栓和非取栓亚组中均观察到相似结果。
关键数值与推荐
- 症状性颅内出血定义为归因于脑实质血肿、蛛网膜下腔出血或脑室出血的NIHSS评分临床恶化至少4分。
- 使用逻辑回归评估替奈普酶与阿替普酶症状性颅内出血风险的差异,校正年龄、性别、NIHSS评分和取栓。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of alteplase for stroke thrombolysis based on evidence from randomized comparisons to alteplase as well as for its practical advantages. There have been no significant differences in symptomatic intracranial hemorrhage (sICH) reported from randomized clinical trials or published case series for the 0.25-mg/Kg dose. OBJECTIVE: To assess the risk of sICH following ischemic stroke in patients treated with tenecteplase compared to those treated with alteplase. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective observational study using data from the large multicenter international Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) collaboration comprising deidentified data on patients with ischemic stroke treated with intravenous thrombolysis. Data from more than 100 hospitals in New Zealand, Australia, and the US that used alteplase or tenecteplase for patients treated between July 1, 2018, and June 30, 2021, were included for analysis. Participating centers included a mix of nonthrombectomy- and thrombectomy-capacity comprehensive stroke centers. Standardized data were abstracted and harmonized from local or regional clinical registries. Consecutive patients with acute ischemic stroke who were considered eligible and received thrombolysis at the participating stroke registries during the study period were included. All 9238 patients who received thrombolysis were included in this retrospective analysis. MAIN OUTCOMES AND MEASURES: sICH was defined as clinical worsening of at least 4 points on the National Institutes of Health Stroke Scale (NIHSS), attributed to parenchymal hematoma, subarachnoid, or intraventricular hemorrhage. Differences between tenecteplase and alteplase in the risk of sICH were assessed using logistic regression, adjusted for age, sex, NIHSS score, and thrombectomy. RESULTS: Of the 9238 patients included in the analysis, the median (IQR) age was 71 (59-80) years, and 4449 patients (48%) were female. Tenecteplase was administered to 1925 patients. The tenecteplase group was older (median [IQR], 73 [61-81] years vs 70 [58-80] years; P < .001), more likely to be male (1034 of 7313 [54%] vs 3755 of 1925 [51%]; P < .01), had higher NIHSS scores (median [IQR], 9 [5-17] vs 7 [4-14]; P < .001), and more frequently underwent endovascular thrombectomy (38% vs 20%; P < .001). The proportion of patients with sICH was 1.8% for tenecteplase and 3.6% for alteplase (P < .001), with an adjusted odds ratio (aOR) of 0.42 (95% CI, 0.30-0.58; P < .01). Similar results were observed in both thrombectomy and nonthrombectomy subgroups. CONCLUSIONS AND RELEVANCE: In this large study, ischemic stroke treatment with 0.25-mg/kg tenecteplase was associated with lower odds of sICH than treatment with alteplase. The results provide evidence supporting the safety of tenecteplase for stroke thrombolysis in real-world clinical practice.
引用
- Warach SJ, Ranta A, Kim J, et al. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. JAMA Neurol. 2023. PMID: 37252708. doi:10.1001/jamaneurol.2023.1449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。